Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies-Reference-Cited by-同舟云学术

Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies

Published:2017-08-03 Issue:11 Volume:26 Page:1338-1346
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Noh Yoojin¹^ORCID,Kang Dae Ryong²^ORCID,Kim Dae Jung³^ORCID,Lee Kwang Jae⁴^ORCID,Lee Sukhyang¹⁵^ORCID,Shin Sooyoung¹⁵^ORCID

Affiliation:

1. College of Pharmacy; Ajou University; Suwon Gyeonggi-do South Korea

2. Center of Biomedical Data Science/Institute of Genomic Cohort, Wonju College of Medicine; Yonsei University; Wonju Gangwon-do South Korea

3. Department of Endocrinology and Metabolism, School of Medicine; Ajou University; Suwon Gyeonggi-do South Korea

4. Department of Gastroenterology, School of Medicine; Ajou University; Suwon Gyeonggi-do South Korea

5. Research Institute of Pharmaceutical Science and Technology (RIPST); Ajou University; Suwon Gyeonggi-do South Korea

Funder

Ajou University Research Fund

Ministry of Science, ICT and Future Planning

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference33 articles.

1. Use of antidiabetic drugs in the U.S., 2003-2012;Hampp;Diabetes Care,2014

2. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes;Nissen;N Engl J Med,2007

3. FDA FDA ALERT #1: 5/21/2007, updated 11/19/2007: FDA adds a new warning about the risk of myocardial ischemia to the boxed warning for Avandia, for treatment of type 2 diabetes 2007 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143406.htm#2007_5

4. EMEA Press release: EMEA recommends new warnings and contraindications for rosiglitazone 2008 http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015420.pdf

5. MFDS Press release: MFDS recommends new warnings and contraindications for rosiglitazone 2010 http://www.mfds.go.kr/index.do?mid=1031&seq=7710&cmd=v&cd=172

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients;Scientific Reports;2023-10-27

2. Prescription changes in patients with gastrointestinal disorders after withdrawal of ranitidine: a nationwide population-based cohort study;Current Medical Research and Opinion;2023-01-03

3. Regulatory post‐market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies;Pharmacology Research & Perspectives;2020-11-09

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus

;Cancer Management and Research;2019-08

5. Association between glucose‐lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy;International Journal of Cancer;2018-12-16